|
| volgende >> |
Tijdschrift beschrijving
Alle jaargangen van het bijbehorende tijdschrift
Alle afleveringen van het bijbehorende jaargang
Alle artikelen van de bijbehorende aflevering
Details van artikel 1 van 5 gevonden artikelen
| Titel: |
Bioequivalence of Two Oral Fluconazole Formulations in Healthy Subjects: a Single Dose, Open-Label, Randomized, Two-Period Crossover Study |
| Auteur: |
Jose Antonio Palma-Aguirre Mireya Lopez-Gamboa Teresita de Jesus Castro-Sandoval Roxana Hernández-González Julian Mejía-Callejas |
| Verschenen in: |
Journal of bioequivalence & bioavailability |
| Paginering: | Jaargang 02 (2010) nr. 02 pagina's 023-027 |
| Jaar: |
2010 |
| Inhoud: |
Background: Fluconazole is a triazole antifungal agentlabeled for use in the treatment of oropharyngeal and esophagealcandidiasis and cryptococcal meningitis, marketedin Mexico in several generic trade names.Objective: The aim of this study was to compare thebioavailability and determine the bioequivalence of one testformulation (fluconazole oral tablet) with its correspondinglist reference-drug formulation in Mexico (a list issuedby Mexican Health Authorities).Methods: A single dose, randomized, open-label, 2-periodcrossover, postmarketing study was conducted. Eligiblesubjects was selected comprising healthy Mexicanadults of either sex, and subjects were randomly assignedto receive 1 test formulation of fluconazole followed bythe corresponding reference drug formulation, or viceversa,with a 1-week washout period between doses. After a 12-hour (overnight) fast, subjects received a single capsule offluconazole 150 mg tablet formulation. For the analysis ofbioequivalence, including Cmax, AUC from time 0 (baseline)to time t (AUC0-t), and AUC from baseline to infinity(AUC0-¥), blood samples were collected at baseline, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours afterdosing. The formulation was considered bioequivalent ifthe geometric mean ratios (test/reference) of the Cmax andAUC were within the predetermined range of 80% to125%. Tolerability was determined by clinical assessment,monitoring vital signs, laboratory analysis results, and subjectinterviews regarding adverse events.Results: A total of 24 subjects were enrolled in the studyThe bioequivalence test drug values were Cmax of 4.44 ±0.79 μg/mL, tmax of 2.59 ± 1.03 h, AUC0-t of 152.21 ± 28.89h. μg/mL, AUC0-¥ of 175.13 ± 48.98 h. μg/mL, and referencedrug values of Cmax of 4.38 ± 0.83 μg/mL, tmax of 2.70± 1.15 h, AUC0-t of 154.67 ± 26.10 r. μg/mL, AUC0-¥ of174.33 ± 31.10 hr. μg/mL.Conclusions: In this study in healthy Mexican adult subjects,a single dose of fluconazole 150 mg of the test formulationwas found to be bioequivalent to the correspondingreference formulation according to the regulatory definitionof bioequivalence based on the rate and extent ofabsorption. Both formulations were generally well tolerated. |
| Uitgever: |
OMICS Publishing Group (provided by DOAJ) |
| Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
Details van artikel 1 van 5 gevonden artikelen
| volgende >> |